Last updated on February 2018
A Multinational Randomized Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer
Brief description of study
The primary objective of the study is to compare overall survival of patients randomized to receiving custirsen in combination with docetaxel (Arm A) with patients randomized to receive docetaxel alone (Arm B).
Clinical Study Identifier: NCT01630733
Start Over
Connect »